Generics & Biosimilars | Association for Accessible Medicines
In the News - AAM CEO Dan Leonard shares the industry's 2021 outlook with Chain Drug Review.
  • Dan Leonard, AAM CEO and President
    2021 Generics and Biosimilars Outlook
    Read AAM CEO Dan Leonard’s 2021 industry outlook—ensuring the sustainability of the generics and biosimilars markets, enhancing the security of the U.S. pharma supply chain and lowering prescription drug costs.
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?
  • GRx+Biosims 2020 On-Demand
    Get on-demand access to key sessions of the GRx+Biosims virtual conference.
  • A group of five multi-ethnic seniors standing together in a park wearing casual clothing, smiling at the camera.
    Generic Savings Add Up for Patients with Cancer and Other Conditions
    No matter what condition you or your family members are experiencing, generic prescription drugs are saving you money.
  • #SecureOurMeds
    Plan to Secure Our Medicines
    The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to #SecureOurMeds. We already produce billions of doses domestically and our plan ensures continued patient access through COVID and beyond.
    Watch Video
  • AAM Blueprint U.S. Supply Chain
    Securing the U.S. Rx Supply Chain
    The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.